基于非凋亡性调节性细胞死亡的特征鉴定用于改善急性髓系白血病预后预测
研究从TCGA和GEO数据库下载AML患者的RNA测序和临床数据,通过Cox和LASSO回归分析确定非凋亡性调节性细胞死亡相关基因(NRG)的预后特征。鉴定出13个NRG特征作为AML患者的独立预后参数,优于其他预后模型。高NRG评分与较短生存和肿瘤突变保留较少相关,高NRG风险患者富集细胞黏附、细胞因子上调和细胞防御反应信号通路,低NRG风险患者可能从免疫治疗中获益最多。
要点
- 13个NRG特征为AML独立预后参数,优于其他预后模型。
- 高NRG评分与较短生存和肿瘤突变保留较少相关。
- 高NRG评分患者可能从抗EGFR和CDK2抑制剂(如厄洛替尼和roscovitine)治疗中获益。
核心结论
- 建立的NRG特征和评分突显其重要临床意义,强调对不同突变亚型进行分层治疗的必要性,并为指导AML患者个性化免疫治疗策略提供新思路。
研究设计与样本
- 从TCGA和GEO数据库下载AML患者的RNA测序和临床数据,通过Cox和LASSO回归分析确定非凋亡性RCD相关基因的预后特征。
主要发现
- 鉴定出13个NRG特征作为AML患者的独立预后参数,优于其他预后模型。
- 较高NRG评分与较短生存和肿瘤突变保留较少相关。
- 高NRG风险患者具有丰富的细胞黏附、细胞因子上调和细胞防御反应信号通路,低NRG风险患者可能从免疫治疗中获益最多。
- 高NRG评分患者可能从抗EGFR和CDK2抑制剂治疗中获益,包括厄洛替尼和roscovitine。
- NPM1和FLT3突变细胞系在多种药物处理后发生改变。
临床怎么用
- 作者认为建立的NRG特征和评分突显重要临床意义,强调对不同突变亚型进行分层治疗的必要性,并为指导AML患者个性化免疫治疗策略提供新思路。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although anti-apoptotic cell death is a common feature of cancer and non-apoptotic regulatory cell death (RCD) is highly correlated with cancer progression and response to therapy, its prognostic role in patients with acute myeloid leukaemia (AML) is unknown. The RNA sequence and clinical data from AML patients were downloaded from the TCGA and GEO databases. The prognostic characteristics of non-apoptotic RCD-related genes (NRGs) were determined by Cox and LASSO regression analysis. Thirteen NRG signatures were identified as independent prognostic parameters in patients with AML that outperformed other prognostic models. Higher NRG scores were associated with shorter survival and less retention of tumour mutations. Although patients with high NRG risk have abundant signalling pathways for cell adhesion, cytokine upregulation, and cellular defence responses, patients with low NRG risk may benefit the most from immunotherapy. Specifically, patients with high NRG score may benefit from treatment with anti-EGFR and CDK2 inhibitors, including erlotinib and roscovitine. The NPM1 and FLT3 mutant cell lines undergo alterations after multiple drug treatments. Our established NRG signature and scoring highlight its vital clinical significance, emphasize the inevitability of stratifying treatment for different mutation subtypes and provide new ideas to guide personalized immunotherapy strategies for AML patients.
引用
- Zheng Y, Weng X, Hu D, et al. Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia. Br J Haematol. 2022. PMID: 36484284. doi:10.1111/bjh.18601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。